Pharmacokinetics and metabolism studies on the glucagon-like peptide-1 (GLP-1)-derived metabolite GLP-1(9-36)amide in male Beagle dogs

scientific article published on 4 March 2014

Pharmacokinetics and metabolism studies on the glucagon-like peptide-1 (GLP-1)-derived metabolite GLP-1(9-36)amide in male Beagle dogs is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.3109/00498254.2014.897011
P698PubMed publication ID24588343

P50authorHeather EngQ99552335
P2093author name stringAmit S Kalgutkar
Raman Sharma
Margaret S Landis
Benjamin D Stevens
Thomas S McDonald
P2860cites workExpression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1Q24563957
Mass spectrometry of peptides and proteinsQ28235966
The Physiology of Glucagon-like Peptide 1Q28373115
Peptide sequence analysisQ33231175
Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptidesQ33788748
Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathyQ34786386
Cardiovascular biology of the incretin systemQ36484283
Utility of in vitro drug metabolism data in predicting in vivo metabolic clearanceQ36750350
Therapy in the early stage: incretinsQ36783865
Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptidesQ37212333
Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapiesQ37735524
GLP-1 based therapies: differential effects on fasting and postprandial glucoseQ37974712
GLP-1 receptor agonists: a clinical perspective on cardiovascular effectsQ38002008
Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesisQ42022343
Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathwaysQ42165735
Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine.Q42479294
GLP-1 (9-36) amide metabolite suppression of glucose production in isolated mouse hepatocytesQ42964903
In vitro metabolism of the glucagon-like peptide-1 (GLP-1)-derived metabolites GLP-1(9-36)amide and GLP-1(28-36)amide in mouse and human hepatocytesQ44317184
Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathyQ45020436
Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathyQ46604606
GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptideQ46637836
Glucagon-like peptide-1(7–37) has a larger volume of distribution than glucagon-like peptide-1(7–36)amide in dogs and is degraded more quickly in vitro by dog plasmaQ58449077
Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy SubjectsQ58449089
P433issue9
P407language of work or nameEnglishQ1860
P921main subjectpharmacokineticsQ323936
P304page(s)842-848
P577publication date2014-03-04
P1433published inXenobioticaQ1360678
P1476titlePharmacokinetics and metabolism studies on the glucagon-like peptide-1 (GLP-1)-derived metabolite GLP-1(9-36)amide in male Beagle dogs
P478volume44

Reverse relations

cites work (P2860)
Q38589032Mechanisms for the cardiovascular effects of glucagon-like peptide-1.
Q38264736Strategic approaches to optimizing peptide ADME properties
Q46341700Why is it so difficult to measure glucagon-like peptide-1 in a mouse?

Search more.